Biogen (BIIB) stock had a bullish inflow of $95.42 million worth of trades on uptick and an outflow of $75.32 million in downticks on Wednesday. The total uptick to downtick ratio stood at 1.27. The net money flow into the stock was $20.1 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $24.8 million. $24.8 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Biogen (BIIB) stock traded down $3.98 , and reached $310.55, a drop of -1.27% over the previous day. On a weekly basis, the stock is -0.65%, over the previous weeks close.
Biogen Inc. has dropped 0.46% in the last five trading days, however, the shares have posted positive gains of 1.44% in the last 4 weeks. Biogen Inc. is up 29.99% in the last 3-month period. Year-to-Date the stock performance stands at 1.37%.
Biogen (BIIB) : Zacks Investment Research ranks Biogen (BIIB) as 3, which is a Hold recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 1.83, which indicates as a Buy.
Biogen (NASDAQ:BIIB): stock was range-bound between the intraday low of $308.74 and the intraday high of $315.99 after having opened at $315.99 on Wednesdays session. The stock finally closed in the red at $315.99, a loss of -1.27%. The stock remained in the red for the whole trading day. The total traded volume was 1,020,123 shares. The stock failed to cross $315.99 in Wednesdays trading. The stocks closing price on Thursday was $314.53.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.